| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:41 UTC |
|---|
| HMDB ID | HMDB0014639 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Darifenacin |
|---|
| Description | Darifenacin, also known as enablex or emselex, belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. Darifenacin is a drug which is used for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin is a very strong basic compound (based on its pKa). Darifenacin is a potentially toxic compound. |
|---|
| Structure | NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide | ChEBI | | (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-a,a-diphenyl-3-pyrrolidineacetamide | Generator | | (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamide | Generator | | Enablex | HMDB | | Darifenacin hydrochloride | HMDB | | Darifenicin | HMDB | | Darifenacin hydrobromide | HMDB | | Emselex | HMDB | | Darifenacine | HMDB |
|
|---|
| Chemical Formula | C28H30N2O2 |
|---|
| Average Molecular Weight | 426.55 |
|---|
| Monoisotopic Molecular Weight | 426.230728214 |
|---|
| IUPAC Name | 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide |
|---|
| Traditional Name | darifenacin |
|---|
| CAS Registry Number | 133099-04-4 |
|---|
| SMILES | NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1 |
|---|
| InChI Key | HXGBXQDTNZMWGS-RUZDIDTESA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Diphenylmethanes |
|---|
| Direct Parent | Diphenylmethanes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylmethane
- Phenylacetamide
- Phenethylamine
- Coumaran
- Alkyl aryl ether
- Aralkylamine
- N-alkylpyrrolidine
- Pyrrolidine
- Amino acid or derivatives
- Carboxamide group
- Primary carboxylic acid amide
- Tertiary amine
- Tertiary aliphatic amine
- Ether
- Carboxylic acid derivative
- Oxacycle
- Organoheterocyclic compound
- Azacycle
- Organic oxide
- Organic nitrogen compound
- Organopnictogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Amine
- Carbonyl group
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0003 g/L | Not Available | | LogP | 4.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.53 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.299 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.44 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 51.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1593.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 220.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 215.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 184.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 164.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 448.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 470.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 641.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1034.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 480.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1446.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 314.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 354.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 294.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 380.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Darifenacin,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1 | 3669.9 | Semi standard non polar | 33892256 | | Darifenacin,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1 | 3317.7 | Standard non polar | 33892256 | | Darifenacin,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1 | 4505.3 | Standard polar | 33892256 | | Darifenacin,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)[Si](C)(C)C | 3694.3 | Semi standard non polar | 33892256 | | Darifenacin,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)[Si](C)(C)C | 3479.4 | Standard non polar | 33892256 | | Darifenacin,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)[Si](C)(C)C | 4331.1 | Standard polar | 33892256 | | Darifenacin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1 | 3891.0 | Semi standard non polar | 33892256 | | Darifenacin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1 | 3572.7 | Standard non polar | 33892256 | | Darifenacin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1 | 4565.2 | Standard polar | 33892256 | | Darifenacin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)[Si](C)(C)C(C)(C)C | 4129.2 | Semi standard non polar | 33892256 | | Darifenacin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)[Si](C)(C)C(C)(C)C | 3877.8 | Standard non polar | 33892256 | | Darifenacin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)[Si](C)(C)C(C)(C)C | 4368.9 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Darifenacin GC-MS (Non-derivatized) - 70eV, Positive | splash10-00lv-2491000000-40c43db64189724fe0c2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Darifenacin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 10V, Positive-QTOF | splash10-004i-0101900000-1979d23256753a983573 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 20V, Positive-QTOF | splash10-03gj-0756900000-6e69c78743e94527add2 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 40V, Positive-QTOF | splash10-0uxs-2910000000-ec1acf0e02b7c0a392f3 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 10V, Negative-QTOF | splash10-004i-0001900000-e8c519b1d7f130de607a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 20V, Negative-QTOF | splash10-004i-4285900000-73144c3d58ba99d76581 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 40V, Negative-QTOF | splash10-0006-9030000000-5dfb7a1ae0753d3d4c11 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 10V, Negative-QTOF | splash10-005c-4005900000-8a58ca84e09117fd29e5 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 20V, Negative-QTOF | splash10-0006-9004100000-2c811675031a777fbc67 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 40V, Negative-QTOF | splash10-0006-9212000000-514c545cfeaf92ef3a8e | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 10V, Positive-QTOF | splash10-004i-0002900000-3905ca525d1dcc4e15f3 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 20V, Positive-QTOF | splash10-004i-0104900000-359dc4da59d626f0edf4 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Darifenacin 40V, Positive-QTOF | splash10-0002-0932000000-13b487199d725fb1e357 | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|